IL-31 antibody (AA 21-120)
Quick Overview for IL-31 antibody (AA 21-120) (ABIN1715124)
Target
See all IL-31 (IL31) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 21-120
-
Purpose
- IL-31 Polyclonal Antibody
-
Cross-Reactivity
- Mouse
-
Predicted Reactivity
- Rat
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from mouse IL-31
-
Isotype
- IgG
-
-
-
-
Application Notes
- WB(1:300-5000),
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
-
Expiry Date
- 12 months
-
-
- IL-31 (IL31) (Interleukin 31 (IL31))
-
Alternative Name
- IL-31
-
Background
-
Synonyms: Interleukin-31, 1700013B14RIK, IL31, interleukin-31 precursor.
Background: Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia and skin lesions, and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.
-
Gene ID
- 76399
Target
-